A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

This publication has 11 references indexed in Scilit:

• EFFECTS OF IN VIVO TREATMENT WITH FK506 ON NATURAL KILLER CELLS IN RATS
  Transplantation, 1991
• Pathologic observations in human allograft recipients treated with FK 506.
  1990
• Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.
  1990
• Early trials with FK 506 as primary treatment in liver transplantation.
  1990
• FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION
  The Lancet, 1989
• A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase
  Nature, 1989
• A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin
  Nature, 1989
• A highly sensitive method to assay FK-506 levels in plasma.
  1987
• Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.
  1987
• FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.
  The Journal of Antibiotics, 1987